Drug Trial Radar · NCT00723502
Efficacy and Safety Study of Finafloxacin Used in Helicobacter Pylori Infected Patients
Last checked: Nov 19, 2026Latest source record: Jun 16, 2009 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
30
Planned (sponsor's estimate)
Start
Sep 2008
Primary completion
Apr 2009
Study completion Apr 2009
Sponsor
- Lead sponsor
- MerLion Pharmaceuticals GmbHIndustry
- Sponsor type
- Industry
- First posted
- Jul 28, 2008
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study is to compare the H. pylori eradication rates with Finafloxacin in combination with Amoxicillin or Esomeprazole. The secondary objective is to evaluate and compare the safety and tolerability of multiple oral doses of Finafloxacin plus Amoxicillin versus Finafloxacin plus Esomeprazole.
Conditions
- Gram-Negative Bacterial Infections
- Helicobacter Infections
- Dyspepsia
Interventions
Finafloxacin + AmoxicillinDrug
Finafloxacin, tablets, 400 mg b.i.d. (8 X 50 mg tablets), oral administration; Amoxicillin, tablet 1000 mg b.i.d. (1 X 1000 mg tablet), oral administration
Finafloxacin + EsomeprazoleDrug
Finafloxacin, tablets, 400 mg b.i.d. (8 X 50 mg tablets), oral administration; Esomeprazole, tablet, 40 mg b.i.d. (1 X 40 mg tablet), oral administration
Primary outcomes
What the sponsor says the trial is designed to measure.
- Eradication of Helicobacter pyloriTime frame: 14 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Dr. Hein
Marburg, Germany
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.